Harbor Advisors’s Moderna MRNA Stock Holding History

Harbor Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,000	Closed	-$238K	–	193
2024 Q2	$238K	Hold	2,000	–	–	0.04%	152
2024 Q1	$213K	Sell	2,000 -1,000	-33%	-$101K	0.04%	157
2023 Q4	$298K	Buy	+3,000	New	+$252K	0.06%	134

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harbor Advisors's MRNA Position: Q3 2024 in Review

Harbor Advisors sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,000 shares — an estimated $238K sold.

Harbor Advisors first reported a position in MRNA in Q4 2023 and held it in 3 quarters. The position peaked at $298K in Q4 2023. 789 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

Harbor Advisors reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
Harbor Advisors sold 2,000 Moderna shares in Q3 2024, an estimated $238K.
Harbor Advisors first reported a position in Moderna in Q4 2023 and held it in 3 quarters.
Harbor Advisors's Moderna position peaked at $298K in Q4 2023.
789 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Harbor Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.